Anita C M Van Oers
Overview
Explore the profile of Anita C M Van Oers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, et al.
Sleep
. 2020 May;
43(7).
PMID: 32396197
No abstract available.
2.
Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, et al.
Sleep
. 2019 Jan;
42(4).
PMID: 30597112
Study Objectives: To assess potential effects of lemborexant on next-morning driving performance in adult and elderly healthy volunteers. Methods: Randomized, double-blind, double-dummy, placebo and active-controlled, four period incomplete crossover study...
3.
Vermeeren A, Vets E, Vuurman E, Van Oers A, Jongen S, Laethem T, et al.
Psychopharmacology (Berl)
. 2016 Jul;
233(18):3341-51.
PMID: 27424295
Rationale: Suvorexant is a first-in-class orexin receptor antagonist for treating insomnia. There is a general concern that hypnotics may impair next-morning driving ability. Objective: The objective of this study was...
4.
Vermeeren A, Sun H, Vuurman E, Jongen S, van Leeuwen C, Van Oers A, et al.
Sleep
. 2015 Jun;
38(11):1803-13.
PMID: 26039969
Study Objective: To evaluate next-morning driving performance in adults younger than 65 years, after single and repeated doses of suvorexant 20 and 40 mg. Design: Double-blind, placebo-controlled, 4-period crossover study....
5.
Vermeeren A, Vuurman E, Leufkens T, van Leeuwen C, Van Oers A, Laska E, et al.
Sleep
. 2014 Mar;
37(3):489-96.
PMID: 24587571
Study Objective: To evaluate next-morning driving performance after middle-of-the-night use of zolpidem 3.5 mg in a buffered sublingual formulation (ZST). Design: Single-center, four-period, randomized, double-blind, placebo-controlled, crossover study. Setting: Maastricht...
6.
Conen S, Theunissen E, Van Oers A, Valiente R, Ramaekers J
J Psychopharmacol
. 2010 Sep;
25(11):1517-23.
PMID: 20855350
Bilastine is a new second-generation H1 antagonist. Although bilastine has been demonstrated to produce little or no performance impairment in laboratory tests, it cannot be excluded that it produces impairments...